Will 3D Bioprinting Turn Disruptor in Healthcare? 
3D bioprinting has come to the limelight recently and a lot of research activities have been undertaken for the same. Creating organ models that can be used for preclinical testing of drugs and other interventional molecules and creating organ scaffolds for clinical transplantation can become a breakthrough in the healthcare domain. Though the technology is yet to be accepted fully among India’s medical sector, current efforts by academics and research labs will ensure that 3D bioprinting provides personalised solutions for individual patients.

How India is Pulling In European Life Sciences Sector
When the world was struggling with COVID-19 in 2020 and 2021, the partnership
between Indian and European organizations proved to be a historic accomplishment
in the field of global life sciences. It was able to deliver more than two billion doses
of the COVID-19 vaccine, which was developed by the University of Oxford and
AstraZeneca, both from the United Kingdom, and manufactured by Serum Institute
of India (SII) in India, to more than 170 countries starting in November 2020,
marking a significant milestone in the global pandemic response. India's economical
production in the biopharma industry allowed it to reach this significant milestone.
India's advantages, including cost-effective manufacturing, a skilled workforce, and
a growing but robust research ecosystem, are making it an attractive destination for
outsourcing and joint ventures. These collaborations have led to the development of
innovative healthcare solutions and have expanded market access for both Indian
and European firms. The India-Europe collaboration in life sciences has evolved into
a dynamic partnership fostering innovation, investment, and shared expertise. While
significant strides have been made in contract research, vaccine production, and
biosimilars, there remains potential for greater collaboration in new drug discovery
sciences. As European companies expand their R&D and manufacturing presence
in India, the mutual focus on academic research and healthcare resilience positions
this partnership as a global leader in life sciences innovation.

Indian Pharma Hits R&D Salvo
Pharma companies are constantly on the quest to discover the next big game-changer drug or therapeutic by leveraging the latest, cutting-edge innovation. While it is notable that biopharma companies eased up on their research and development (R&D) spending in FY 2022-23 after the world was hit by COVID-19-  induced economic slowdown, the budget for R&D has witnessed a steady increase. Departing a bit from their traditional drug portfolios, companies are increasingly focusing on R&D in next generation therapies to drive innovation, particularly in complex generics, biosimilars, cell and gene therapies and novel drug delivery systems.

BioPharma’s Transformative & Strategic  OUTLOOK 2025
The Indian biopharma industry witnessed notable transformative developments and
announcements, marked by innovation, regulatory advancements, and market expansion this year. From achieving global recognition in biosimilars to advancing biomanufacturing capabilities and precision therapeutics, the sector has solidified its role as a key player in the global pharmaceutical landscape. This progress underscores India’s strategic focus on leveraging its robust infrastructure, skilled talent pool, and government support to meet the evolving demands of the healthcare industry. Key developments in 2024 include an increase in
biosimilar approvals, enhanced collaborations for biologics and vaccines, and a focus on potential investments in cutting-edge technologies like Artificial Intelligence (AI), continuous manufacturing, and automation through biofoundries. Looking ahead, the industry is well-positioned to align with emerging trends that are shaping the global biopharma landscape for 2025 and beyond.These include the growing emphasis on precision medicine, a shift towards sustainablebiomanufacturing practices, and an increase in demand for advanced therapies such as cell
and gene therapies. With over $200 billion worth of biologic patents set to expire by 2030, Indiancompanies are poised to play a pivotal role in driving the next wave of innovation and accessibilityin biologics and biosimilars.

Will Boosting Biofoundries Transform India's Biomanufacturing Landscape?
Biofoundries hold the potential to emerge as the backbone of biomanufacturing 
and synthetic biology, offering integrated infrastructure to streamline the design, 
construction, and testing of genetically engineered organisms. Biofoundry is a place where biomanufacturing meets automation. The highly modular structure of a 
biofoundry helps accelerate the design-build-test-learn (DBTL) workflow to deliver 
products fast and in a streamlined fashion. Advanced platforms to enable rapid, 
high-throughput experimentation, and automating processes that were once labourintensive and time-consuming is a central theme. India has come up with multiple initiatives to support and set up biofoundries, including the BioE3 (Biotechnology for Economy, Environment and Employment) Policy, the Bio-RIDE scheme, and the Vigyan Dhara scheme. The BioE3 Policy lays out plans for accelerating the transition to biomanufacturing by promoting integrated use of Artificial Intelligence (AI), digitalisation with ‘omics’, and upstream biotechnology innovations through bio-AI hubs, biofoundries, and biomanufacturing hubs across the country. With the new BioE3 Policy in place, coming years will provide insight into how biofoundries will play a role in boosting innovation, scale-up and commercialisation of biobased products. In addition, with a Global Biofoundry Alliance now established to coordinate biofoundry activities and innovations worldwide, the question arises: how is India positioned in this rapidly evolving field, and what role do biofoundries play in India’s biomanufacturing initiatives? 

BHARAT EYES GLOBAL BIOMANUFACTURING DOMINANCE: Boosting Innovation, 
Collaboration & Entrepreneurship with BioE3 Policy Bharat has demonstrated a strong economic growth in the past decade and is poised to be amongst the global leaders in the next industrial revolution by leveraging emerging technologies 
and new innovative solutions. Bharat is competitively positioned to be amongst the global leaders in futuristic manufacturing that leverages living systems. Biomanufacturing can fundamentally transform the global economy from today’s consumptive manufacturing paradigm to the one based on regenerative principles. Biomanufacturing refers to the use of engineered microbial, plant, and animal (including human) cells with increasing precision and control to produce 
commercially important products on scale. These are versatile processes that have the potential to create bio-based products allowing efficient utilisation of resources, in a scalable and costeffective manner with reduced environmental impact. Keeping in view the national priority of steering Bharat on the path of accelerated ‘Green Growth’, an integrated BioE3 (Biotechnology for Economy, Environment and Employment) Policy for “Fostering High-Performance Biomanufacturing” with an aim to make a green, clean, prosperous, and self-reliant Bharat was released on September 12 at Global Bio-India (GBI) 2024. 

Can India Reclaim API Throne from China?
Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs). India is the source of around 60,000 generic brands across 60 therapeutic categories and manufactures more than 500 different APIs. However, India imports about 70 per cent of its APIs from China as it’s a cheaper option than manufacturing them domestically. There were 58 APIs in which India was heavily dependent on China. In the case of 45 APIs, India was dependent on China for 100 per cent of imports. Out of these 58 APIs, 29 APIs are manufactured through fermentation and 29 APIs are manufactured through chemical synthesis. The Department of Pharmaceuticals has drawn up a list of 56 APIs to prioritise them for the Make-in-India initiative. These include APIs or bulk drugs that go into the making of essential drugs, such as antibiotics, anti-HIV medicines, and the humble but indispensable paracetamol. The plan to make APIs in India has been in the works for some time but the Council of Scientific and Industrial Research (CSIR ) was engaged only recently. Let’s see how these steps taken by the government help to promote the production of KSMs and APIs in India in the coming years.

Why INDIA must turn BIOSIMILAR POWERHOUSE by 2030
Biosimilars could potentially enhance patient access to treatment of various malignant and nonmalignant conditions by reducing costs. Since the introduction of the first biosimilar in 2000 in India, a vaccine for hepatitis B, the development and utilisation of "biosimilars or similar biologics" have experienced significant growth. Each year, regulatory bodies are approving numerous similar biologics for the management of both cancerous and noncancerous illnesses. India has firmly positioned itself as a key player in the global production of similar biologics, benefiting from its large population. Despite the considerable potential and high expectations for India, there are substantial challenges that must be overcome to 
maintain this leadership position. To realise their full potential and sustain their global leadership, Indian biopharmaceutical companies must enhance their technological capabilities and enhance the skills of their workforce. This will require a supportive environment from both the government and regulatory agencies.

MediTech Stackathon 2024 to Drive Explosive Growth
India's medtech industry holds immense potential, with projections estimating a growth rate of 28 per cent annually, reaching a size of $50 billion by 2030. Currently, India is the fourth largest market for medical devices in Asia and among the top 20 globally. Net imports for 2022-23 stands at $4.101 billion with import coverage ratio of 0.45. The sector has witnessed a surge in imports, driven primarily by countries like the US, China, and Germany, however, India's robust policy ecosystem presents opportunities for exports and reducing import dependence through domestic manufacturing. Exports have overtaken imports in consumables and disposables during last year. The industry now needs to continue with the momentum in other pillars of the medtech sector. Against this backdrop of immense potential, the Department of Pharmaceuticals launched Meditech Stackathon 2024, which
seeks to harness the collective expertise of stakeholders to propel the industry towards unprecedented heights of innovation and self-reliance. With optimal support and participation from all stakeholders, initiatives like Meditech Stackathon will take the Indian medtech industry to the next levels to become self-reliant.

How Deep Tech is Powering India's Biopharma Future
Advancements in cutting-edge innovative  technologies and the increasing  availability of  data have enabled various domains of the biotech and pharma industries to leverage resourceful approaches in driving progress, maintaining 
competitive advantage and accomplishing the ultimate goal of improved patient outcomes. Deep tech ventures, also referred to as hard tech  as opposed to regular digital platforms, primarily focus on the fundamental core issues of a business. For India to become an ‘innovation hub’, with concerted transformative efforts of leaders 
and experts in life sciences, biotech, pharma, and healthcare, deep tech is pivotal. Experts opine that the next wave of startups from India, which is already gaining considerable traction, would be on  deep tech and IP-based devices. Let's take a closer  look at India’s deep tech startup landscape and the vision of a successful deep tech ecosystem.

India’s Life Science Instrumentation Industry: A Disruptor with Global Ambitions?
The Indian laboratory and analytical instrument industry is on the brink of a
transformative journey, propelled by rapid technological advancements and a growing emphasis on indigenous innovation. With the convergence of cutting-edge technologies such as Artificial Intelligence, Machine Learning, Big Data Analytics, Online and Atline testing, Cloud computing, and Process Analytical Technologies, the industry is poised for accelerated growth and expansion. Experts from different fields of the industry have highlighted the burgeoning opportunities for domestic players in the laboratory equipment and analytical instrument segment, exploring the evolving landscape, challenges, and strategies for fostering innovation and competitiveness.

Adopting ‘Green Approach’  in Drug Discovery
In the fast-changing global industrial arena, sustainability has become quite crucial. It is a critical issue across multiple  industries; the healthcare and clinical research sectors are no exception. Hospitals and clinical facilities produce tonnes of waste alongside carbon emissions. Medical research consumes non-renewable resources at a staggering rate, which can have a long-term impact on the environment. Sustainable drug discovery and development is positioned as a key initiative in the longdrawn fight against climate change and reducing the detrimental impact on the environment, linked with the health and clinical industry. Let’s explore how India can nail this ‘green target’.

What’s Shaking Up India’s Life Sciences Real Estate Sector?
India, in the last few decades, has witnessed the IT and manufacturing sectors invest heavily in real estate and infrastructure. However, in the post-pandemic era, we see life sciences companies require space to innovate, for R&D, and manufacture at scale. The demand for life sciences-related real estate has significantly increased. Both greenfield and brownfield projects have surged, as the pandemic fuelled the demand for locally manufactured pharma and medical products. This story attempts to encapsulate the changing facets of the life sciences real estate market in India, where the country is remarkably progressing in innovation and R&D, which in turn are fuelling the demand for specialised facilities, biotech/MedTech parks, research hubs with modern amenities and collaborative multidisciplinary ecosystems under one roof.

Can organoids usher in cheap & effective cancer therapeutics?
Dozens of science and technology development payloads returned to Earth from the International Space Station (ISS) as SpaceX’s 29th Commercial Resupply Services
(CRS) mission, contracted by NASA, successfully concluded on December 22, 2023. More than 30 payloads sponsored by the ISS National Laboratory returned on this mission, many of which were life science investigations aimed at benefiting
humanity by improving care for patients on Earth. One among the payloads was an investigation from the University of California, San Diego (UCSD), which studied microgravity’s effects on stem-cell derived brain organoids (lab grown replicas of human organs). While this might seem like science fiction, the story of organoids dates back to 1907. Fast forward to today, these tiny replicas of human organs are experiencing a dramatic surge in popularity, transforming the face of drug discovery research. Dubbed as powerful ‘human modelling systems’, organoids are paving the way for personalised medicines and shaking up the global drug development scene.
India, too, is joining the bandwagon. Let’s explore the world of organoids and how it is pushing the boundaries of personalised medicine research and precision oncology.

Can Biotech Industry Hit $150B by Leveraging Technology, Innovation & Startups?
The biotechnology industry is currently navigating a complex landscape. While revenues have normalised after the COVID’s surge, the looming patent cliff and increased regulatory pressures pose significant challenges. Despite these obstacles, the industry’s long-term potential remains strong, fuelled by a robust innovation pipeline and opportunities for operational efficiency. Biotech companies, according to a report by NoyMed CRO, can secure future growth and address market challenges by focusing on capital allocation, establishing beneficial partnerships, and leveraging technology. Though the path forward is complex, the future of the biotechnology industry remains bright in 2024 as India has set target of reaching $150 billion by 2025 due to its inherent strengths and dedication to innovation.

From Exponential Growth to PHARMA BOOM
The Indian pharmaceutical industry is experiencing a dynamic growth landscape, marked by strategic initiatives such as partnerships, investments, Memoranda of
Understanding (MoUs), and collaborations. Despite geopolitical uncertainties like
the Israel-Palestine and Russia-Ukraine conflicts lingering in 2023, the healthcare
and pharma sector in India continues to gain momentum through new investments
and collaborative efforts. Major global players are actively engaging in partnerships, MoUs, and collaborations to secure a substantial global market share.
In 2023 alone, more than 30 partnerships, MoUs and other collaborations have been
forged to boost India’s pharmaceutical growth trajectory. The Indian pharmaceutical products market is projected to hit $130 billion by the end of 2030.

AI-Driven Therapeutics for DIABETES
Diabetes mellitus, a chronic metabolic non-communicable disease (NCD), has attained epidemic proportions worldwide. Several studies conducted over the last two decades have revealed a huge burden of diabetes in India, which translates to a large population of individuals at risk of not only cardiovascular disease but also chronic complications of diabetes such as kidney, foot, and eye disease. The cost of 
treating them is crippling not just individuals, but also the society and the country as a whole. For instance, diabetic foot ulcers and infections are responsible for more than 30 per cent of hospitalisations related to diabetes mellitus. On the other hand, there is a higher prevalence of diabetic retinopathy among the urban population than in the rural population. India must step up state-specific policies and technological interventions on a war footing to arrest the rapidly rising epidemic of diabetes.

Transforming Healthcare With Generative AI
Generative AI is making a significant impact in the fields of life sciences and healthcare, transforming the way research, diagnosis, and treatments  are  conducted. By leveraging the power of Generative models, researchers are now exploring ways to generate synthetic data, simulate biological processes, optimize treatment strategies, and facilitate the development of novel therapeutics. This technology is the latest trend that has got global and India’s C-Suite health science professionals explore its implications to develop indigenous solutions. This story, therefore, explores how Generative AI is selling itself to emerge as the new frontier 
in the horizon for the booming healthcare industry. Highlighting some of the significant developments in this technology space, this article also has a few Indian leaders voicing their opinions on exploring Generative AI to progress their businesses and services.

Rise of HEALTHCARE WEARABLES
Wearable technology is becoming increasingly popular in the healthcare industry.
These devices can track a variety of health metrics, including heart rate, blood pressure and sleep patterns. They can also be used to provide remote patient monitoring and early warning systems. The wearable healthcare market in India is rapidly growing due to the increasing awareness of health and fitness among the Indian population, the prevalence of chronic diseases and the government’s support for the adoption of wearables. Of course, there are a few challenges that need to be addressed, such as the lack of regulatory guidelines for wearables, the high cost of some devices and the lack of awareness about the benefits of wearables among the general public. Despite these challenges, the wearable healthcare market in India is expected to continue to grow in the coming years. This growth will be driven by the increasing demand for wearables from consumers and healthcare providers. Let’s explore further.

The verdict is out. And the result has drawn applause – for the industry captains who are winners of the Indian Bio & Health Sciences Industry awards and also for the Jury members who managed this tough task in a two-hour-long deliberation. Since its institution in 2003, the BioSpectrum Excellence Awards honour the achievements of the Indian Bio & Health Sciences Industry leaders. The Annual Gala Awards Nite on June 30, 2023, where these were given away, has been the most eagerly awaited event in the industry.

Can India Create 50K BIOTECH STARTUPS?
2021 was a landmark year for the startup ecosystem when for the first time biotech industry in India recorded over 1000 new startup registrations in a single year, as per the Bioeconomy Report 2022. Dr Jitendra Singh, Union Minister of Science & Technology, Government of India, has revealed that the number of Biotech startups in the country has increased from 50 to over 5,000 in the last 8 years, because of the support and enabling environment provided by Prime Minister Narendra Modi since
2014. It is expected to cross the figure of 10,000 by 2025, he said.

Could 7.5% R&D Spends Make India PHARMA INNOVATION HUB?
Areport by India Brand Equity Foundation (IBEF) stated that India’s domestic pharmaceutical market was estimated at $42 billion in 2021, which is likely to reach $ 65 billion by 2024 and may further expand to reach nearly $120-130 billion by 2030. The country’s vast pool of scientific talent, strong system of higher education, low operating costs, conducive regulatory environment and supportive government
policies have made it an attractive destination for drug development, clinical trials, and commercial manufacturing. A growing population, significant R&D investments, a modernised manufacturing base and the prevalence of chronic diseases have fuelled the growth of the pharma sector. And the backbone of the success can be largely attributed to robust R&D measures in recent years. Post COVID-19, pharma players have increased their R&D investment.

BIOTECH INDUSTRY LEADERS 2021-22
Serum Institute of India continues to lead the Indian Biopharmaceutical Industry Survey 2022 . BioSpectrum India brings to you the survey results of the Biotechnology Industry, across verticals such as biopharma, bioservices, industrial enzymes, medical devices and diagnostic sectors, for FY 21-22. Read more to find out the winners of our biotech industry survey 2022.

India’s vaccine SUPREMACY
India has been able to mark its presence in both the human and livestock vaccine domain, thanks to rigorous research undertaken by government institutes and private vaccine manufacturers. Vaccines made by Indian companies have taken the country to newer heights and were lauded by the rest of the world as well, during the pandemic for India’s capacity to deliver vaccines to many nations in urgent need of jabs. We take a historical glance at India’s steady growth and prowess in the vaccine manufacture and research sphere since the 19th century, catering to inoculations for humans and livestock alike.

Leveraging  Early Cancer Detection Tech
Cancer is fast turning into an ‘epidemic’ and is the second leading cause of death 
globally. As per the Globocan Report of 2020, the annual global burden of cancer 
in 2020 in the country had hit the 1.93 crore mark with an annual death of 1 crore. 
The projected annual new cases globally will be 2.84 crore in 2040. According to 
the same report, the number of new cancer cases in India will be a whopping 17 
lakh annually by 2035. In light of such alarming numbers, early detection still holds 
the key to cancer prevention. Though several technologies have been launched that 
can provide solace to the medical fraternity and patients alike in early detection, 
awareness on the disease and pre-testing remains a challenge in India. There are 
a few ‘Breakthrough Tech’ that hold a lot of promise. For instance, the Imperial 
College London has recently developed a surgical knife capable of identifying 
tumours that can detect endometrial cancer within seconds. The surgical knife 
could aid the treatment strategies for cancer by enhancing the diagnosis time and 
giving the go-ahead for treatment. Let’s explore some notable new technologies 
and also try to uncover the challenges in the fight against cancer.

How genomics Can REVOLUTIONISE HEALTHCARE
A genomic revolution is taking place in India, where the value of genomic tests is being recognised in the prevention and diagnosis of diabetes, cardiovascular, cancer, carrier status, among others. Having the power to identify accurate preventive solutions to chart out treatment options for patients, predictive genomic testing is seen as the next major weapon in the arsenal of cutting-edge healthcare tech that can improve patient outcomes without relying on a curative approach. Let’s learn more from industry leaders and experts in the field of leveraging genomics.

Can INDIA Dethrone CHINA In API PRODUCTION?
The past decade has witnessed a steady growth and commitment of the Indian government in addressing issues like ‘self-reliance and self-sufficiency’ in all aspects of governance and decisions. While sops and subsidies were, indeed, crucial to many concerns of industries and stakeholders, key decisions and schemes were lacking, until numerous ‘Aatmanirbhar Projects’ were kicked off by the Centre. One such crucial initiative addresses the need for Bulk Drugs Parks in India, making the country less dependent on Chinese Active Pharmaceutical Ingredients (APIs), providing more employment and generating more revenue that will add to the country’s GDP. A laudable step has been taken with the launching of three Bulk Drugs projects across three states in the country, with an estimated time of completion set at 5 years. We shall take a closer look at what the project entails and seek expert views from a few industry stalwarts.

Is AMR Modern-day FRANKENSTEIN’S MONSTER?
Antimicrobial Resistance (AMR) continues to pose a significant public health problem in terms of mortality and economic loss. The rising AMR is a matter of huge concern that needs to be tactfully handled and health authorities of several countries, including India, have formulated action plans for its containment. Significant efforts by the government, an active involvement of startups and diagnostic players is a good start. The question remains, whether this will be enough.

Welcome Spike In mRNA TECH?
At least three decades in the making, mRNA vaccine technology has come a long way indeed. While many researchers and scientists worked on mRNA technology, tirelessly burning the midnight oil, a few names do come to the forefront. Dr Robert Malone, developmental biologists Paul Krieg and Douglas Melton, and molecular
biologists Tom Maniatis and Michael Green have been the notable researchers who paved the way for this technology. At the same time, there are doubts raised about the safety and efficacy of mRNA vaccines. Moreover, challenges associated with the manufacture and the logistic needs of the mRNA vaccines are also some of the areas that need more focus and innovation. Let’s dig deeper into the world of mRNA tech.

DRIVING UP DRUG DISCOVERY
 As India takes baby steps in the field of drug discovery, it becomes crucial that the government steps up and provides requisite support to usher in a conducive environment for pharma companies to excel. Concrete measures are warranted to boost and promote drug discoveries by Indian players to add another dimension to the larger Aatmanirbhar Bharat mission.

Bio Spectrum  Cover - BioSpectrum Indian Feb 2025 Edition

BioSpectrum Indian Feb 2025

Bio Spectrum  - BioSpectrum Indian Feb 2025

Bio Spectrum  Cover - BioSpectrum India Jan 2025 Edition

BioSpectrum India Jan 2025

Bio Spectrum  - BioSpectrum India Jan 2025

Bio Spectrum  Cover - BioSpectrum India Dec  2024 Edition

BioSpectrum India Dec  2024

Bio Spectrum  - BioSpectrum India Dec  2024

Bio Spectrum  Cover - BioSpectrum India  Nov 2024 Edition

BioSpectrum India  Nov 2024

Bio Spectrum  - BioSpectrum India  Nov 2024

Bio Spectrum  Cover - BioSpectrum India Oct 2024 Edition

BioSpectrum India Oct 2024

Bio Spectrum  - BioSpectrum India Oct 2024

Bio Spectrum  Cover - September 2024 Edition

September 2024

Bio Spectrum  - September 2024

Bio Spectrum  Cover - August  2024 Edition

August  2024

Bio Spectrum  - August  2024

July 2024

Bio Spectrum  - July 2024

June 2024

Bio Spectrum  - June 2024

May 2024

Bio Spectrum  - May 2024

April 2024

Bio Spectrum  - April 2024

March 2024

Bio Spectrum  - March 2024

Bio Spectrum  Cover - February 2024 Edition

February 2024

Bio Spectrum  - February 2024

Bio Spectrum  Cover - January 2024 Edition

January 2024

Bio Spectrum  - January 2024

Bio Spectrum  Cover - December 2023 Edition

December 2023

Bio Spectrum  - December 2023

Bio Spectrum  Cover - November 2023 Edition

November 2023

Bio Spectrum  - November 2023

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.

March 2013

1. お客様は、Magzter.com、アプリケーション、およびそのサービスの使用は単独でご自身の責任で行うことに同意します。 Magzter.com、その関連会社、従業員、サードパーティのコンテンツ プロバイダーは、サービスが完全に中断されないこと、エラーがないこと、不正行為に対して確実であることを保証しません。また、Web サイトや製品が期待または約束したとおりの正確な結果が得られることも保証しません。

11. サービスおよびすべての出版物は、「現状のまま」および「入手可能な状態」で提供されます。 MAGZTER、その関連会社、サプライヤー、ライセンサーおよび代理店は、明示的か黙示的かを問わず、商品性、特定目的への適合性、および権利侵害の非侵害に関する黙示的な保証を含むがこれらに限定されない、あらゆる種類の保証を明示的に否認します。上記を制限することなく、MAGZTER もその関連会社、サプライヤー、ライセンサー、代理店も、(I) サービスがお客様の要件を満たすこと、(II) サービスが中断されず、タイムリーに、安全に、またはエラーが発生しないことを保証しません。 III) サービスの使用から得られる情報、または出版物に含まれる情報が正確または信頼できるものである、または (IV) 出版物またはサービスの品質がお客様の期待に応えるものであること。信頼できるインターネット接続とデバイスの取得と維持については、お客様が単独で責任を負います。 MAGZTER は、お客様がコンテンツをダウンロードできないことについては責任を負いません。ダウンロードまたはサービスの使用を通じて取得したマテリアルは、お客様自身の裁量とリスクで行われ、かかるマテリアルのダウンロードに起因するコンピューター システムまたはモバイル デバイスへの損害またはデータの損失については、お客様が単独で責任を負うものとします。口頭か書面かを問わず、お客様が magzter から、またはサービスを通じて、またはサービスから得たアドバイスや情報は、いかなる保証も生じません。

2.お客様は、その情報を真実、正確、最新かつ完全なものに保つために維持し、速やかに更新するものとします。あなたは、自分のアカウントとパスワードの機密性を維持し、自分のコンピュータへのアクセスを制限する責任を負い、すべてのコンテンツとサービスの選択と使用を含む、自分のアカウントで行われるすべての活動に対する責任を受け入れることに同意します。

3. いかなる場合においても、Magzter.com、ウェブサイトおよびアプリケーション上のコンテンツの作成、制作、配布に関与する個人、団体、第三者は、契約上または法的責任を負いません。 Magzter.com の使用中または使用中にお客様に発生した直接的、間接的、付随的、特別、および結果的。 Web サイトに登録するか、アプリケーションをダウンロードすることにより、このセクションに記載されている規定が Web サイトおよびアプリケーションのすべての使用およびコンテンツに適用されることに同意するものとします。

3. Magzter からの事前の書面または許可がない限り、ここに公開されているものはすべて Magzter またはそのライセンサーの専有財産であるため、Magzter から取得したコンテンツを変更、コピー、配布、販売してはなりません。このような不正使用は、著作権法や商標法を含む適用法に違反する可能性があるため、Magzter はこれらを厳しく禁止し、そのような違法行為が証明または検出された場合は、アクセスとアカウントを停止します。また、これらの不正行為によって生じた損害についても責任を負う必要があります。出版物の法的所有者が許可する場合を除き、お客様は、サービスを通じてアクセスした出版物をダウンロードすることによって所有権を取得しないことを承認するものとします。著作権法で明示的に要求されている場合、またはサービスの機能によって許可されている場合を除き、変更、リバース エンジニアリング、公開、送信、表示、譲渡または販売への参加、派生作品の作成、またはいかなる形であっても商業的に利用または提供することはできません。 Magzter およびかかるコンテンツの所有者の明示的な許可なしに、アプリのコンテンツ、出版物、またはそれらの一部を第三者に提供すること。当社は、明示的か黙示的かを問わず、Magzter または Magzter のライセンサーの知的財産に対するライセンスを付与しません。

5. あなたは、Magzter.com が他のユーザーや第三者、またはそのコンテンツのいかなる種類の中傷的、攻撃的、または違法な行為に対して責任を負わないこと、および前述の行為による傷害のリスクは完全にあなたにあることを特に認めます。

8. Magzter は、お客様が本利用規約および Magzter が定めるその他の運用規則に準拠しているかどうかを判断する目的で、お客様が公開および入力したコンテンツを監視するすべての権利を留保します。 Magzter は、コンテンツについて決定を下し、独自の意志で削除する権利を有します。

9. Magzter は出版物の販売代理店であり発行者ではないため、Magzter は雑誌に掲載されている意見、アドバイス、声明、サービス、オファーなどを含むコンテンツに対する編集管理を行いません。したがって、Magzter は、そこで提供される情報や事実、または公式の資格に従って行動する Magzter の認定従業員以外の者がサービスを通じて利用できる情報や事実の正確性や信頼性について責任を負いません。したがって、当社には出版物に対する編集上の管理権がありません。本サービスが提供する出版物で行われた意見、アドバイス、声明、サービス、オファー、または第三者によって表明または利用可能にされたその他の情報またはコンテンツは、それぞれの著者または出版社のものであり、第三者のものではありません。マグザー。 Magzter は、サービスを通じてまたは出版物から得た情報への信頼によって生じた損失または損害に対して責任を負いません。本サービスには、他のインターネット サイトおよびサードパーティのリソースへのリンクが含まれている場合がありますが、Magzter は、そのようなリンクされたサイトで利用可能な通信またはマテリアルについては一切の責任を負いません。これらのリンクは便宜のためにのみ提供されています。サードパーティのサイトにアクセスしたり、サードパーティのサイトを通じて注文したりするときに適用される利用規約を理解するのは、お客様自身の責任です。

不快なコンテンツの詳細（プラットフォーム上のリンクを含む）

お気に入りの作品をダウンロードすれば、いつでもどこでもオフラインで読むことができます

愛する人に Magzter ギフト カードをすぐに贈り、何千ものベストセラー タイトルの中からお気に入りの雑誌や新聞を自由に読めるようにしましょう。

Gift your loved ones with a Magzter Gift Card instantly and give them the freedom to read their favorite magazines from thousands of best-selling titles.

{{magCount}}冊の人気のインターナショナル雑誌からお気に入りの雑誌を自由に選べるMagzterギフトカードを、大切な人に今すぐ贈りましょう。

Girish Ramdas は、世界的なデジタル出版ビジネスで話題を呼んでいる、ニューヨークを拠点とする新興企業 Magzter の共同創設者兼 CEO です。 Magzter は 2011 年のサービス開始以来、150 か国以上から 9,000 万人のユーザーを獲得しており、世界中の 4,500 以上の出版社から数千冊の雑誌、新聞、書籍が提供されています。彼は、印刷物、モバイル、Web 開発を含むクロスプラットフォーム出版において 25 年以上の経験があります。この期間中、彼は 3 つの新興企業を共同設立し、経営して成功を収めてきました。彼は雑誌社のデジタル化を可能にし、デジタル世界でコンテンツの収益化を支援してきました。ギリッシュは、オンライン、モバイル、出版エコシステムにおける深い業界経験により、世界中のプラットフォームにわたるデジタル コンテンツの取得、マーケティング、収益化の専門家となっています。

当社のプラットフォーム上で不快なコンテンツに遭遇した場合、当社はお客様の懸念に対処するために苦情救済ポリシーを導入しました。

Magzter Inc. (「当社」、「当社」、「当社」) は、お客様がご自身の個人情報がどのように使用および共有されるかについて関心を持っていることを承知しています。当社のプライバシー慣行の詳細については、次のプライバシー ポリシー(「ポリシー」) をお読みください。当社が運営するウェブサイトおよびそのサブドメインのいずれかにアクセスするか、当社のモバイル アプリケーションやその他のコンテンツ配信方法(総称して「サービス」) を使用することにより、概要が説明されている慣行およびポリシーに同意したことになります。本ポリシーに記載されており、お客様は、当社がお客様の情報を以下の方法で収集、使用、共有することに同意するものとします。

Magzter Inc. は、世界最大かつ急速に成長しているセルフサービスのクロスプラットフォーム デジタル ニューススタンドで、2011 年の創業以来 9,000 万人を超えるユーザーがおり、40 以上のカテゴリ、60 以上の言語にわたる数千の雑誌や新聞を扱っています。ニューヨークに本社を置く Magzter は、アムステルダム、ロンドン、メキシコシティ、チェンナイ、ムンバイ、ニューデリー、バンガロール、シンガポールに現地拠点を置いており、間もなく他の国にも拡大する予定です。 2011 年 6 月に世界的起業家であるギリッシュ ラムダス氏とビジェイ ラダクリシュナン氏によって設立された Magzter は、世界中の雑誌や新聞の出版社が自社のタイトルのデジタル版を作成し、世界中の消費者に配信できるようにします。

Magzter は、ユーザーに安全なプラットフォームを提供することに尽力しています。 Magzter は、パブリッシャーがコンテンツを配布するためのプラットフォームにすぎないことに注意してください。当社は、当社のプラットフォームで公開されるコンテンツを管理または推奨しません。当社は、発行者の行動またはそのコンテンツに対して責任を負いません。

Magzter は、コンテンツまたはコンテンツの一部が権利を侵害したために損害を被った、または費用が発生した当事者を補償する責任を負いません。 Magzter は、第三者の権利を侵害するコンテンツまたはコンテンツの一部に起因する権利侵害について、民事裁判所で法的措置を講じる責任を負いません。

Magzter は、Magzter GOLD と呼ばれる世界最大の「読み放題」サブスクリプション サービスを提供しています。これにより、デジタル読者は月額サブスクリプション料金で 9,000 以上の雑誌や新聞に無制限にアクセスできます。 Magzter はまた、アプリ向けの革新的な ezRead 2.0 機能により、世界最大の記事数を誇ります。これにより、スマートフォンや小さな画面のモバイル ユーザーは、本来の楽しみ方で雑誌コンテンツを楽しむことができます。読みやすく、素晴らしいビデオと高解像度の写真が付いています。

名前

Magzterでのコンテンツ発行に関するサポートが必要は場合は、このフォームに記入してください

 Magzter に入社する前は、Dot Com Infoway (DCI) および Galatta Media の社長を務めていました。彼の任務には、戦略的マーケティング、パートナーシップ開発、コンテンツの世界的な収益化が含まれていました。 DCI は、2000 年には 3 人だった小さなチームから、2011 年には 300 人にまで成長し、世界中のクライアント向けに Web、ソフトウェア、アプリの開発を手がけていました。

Magzterの開始以来、お客様に最高のニューススタンドテクノロジーとサービスを提供するため、世界各国の組織や機関と提携することに尽力してきました。雑誌の購読を顧客に提供したい場合や単に詳細に興味がある場合など、お気軽にお問い合わせください。Magzterはお客様のビジネスの成長を支援いたします。お問い合わせ内容について、以下の質問票にご記入ください：

{{trailText}}無料でお試しください

{{trialPackText}}無料でお試しください

 DMCA では、元の DMCA 通知を提出した当事者が反対通知のコピーを受け取ってから 10 営業日以内にお客様に対して訴訟を起こさない場合、当社は削除されたコンテンツを復元することができます。

このポリシーは、お客様がサービスにアクセスする際に当社が収集する、個人を特定できる情報(「個人情報」) およびお客様およびお客様のコンピューターまたはデバイスに関するその他の情報の当社の取り扱いを対象としています。以下で詳しく説明するように、当社はお客様から個人情報を収集することがあります。当社はこの個人情報を、当社の製品、サービス、コンテンツ、広告をパーソナライズ、提供、改善するため、またお客様がユーザー アカウントとプロフィールを設定し、お客様に連絡し、特定の製品やサービスに対するお客様のリクエストを満たし、お客様によるサービスの使用状況を分析するため。場合によっては、当社は一部の個人情報を第三者と共有する場合もありますが、これはポイント 4 に記載されているとおりに限られます。

このタイトルは Magzter GOLD サブスクリプションに含まれています

コンテンツの品質を分析し、パブリッシャーに適切なフィードバックを提供するため

当社では、不快なコンテンツに関するあらゆる苦情に対応する苦情担当者を任命しています。

不快なコンテンツに関する苦情は、上記の電子メール アドレスに電子メールで苦情担当者に送信するようお願いします。また、苦情を申し立てる際には、以下の詳細を提供するようお願いします。

さまざまな雑誌、書籍、ニュース、雑誌および出版物関連コンテンツ (総称して「出版物」と呼ばれます) を注文、購読、配信を受け取り、これらの出版物のデジタル版を配信する機能を提供するアプリ

c.また、パーソナライズされた推奨事項を作成するために、アプリケーションの使用に関連する情報も収集します。お客様がサードパーティのアカウント資格情報を当社に提供した場合、お客様がそのような送信を許可した場合、それらのアカウント内の一部のコンテンツおよび / または情報(以下「サードパーティのアカウント情報」) がお客様のアカウントに送信される可能性があること、およびそのサードパーティのアカウントが当社のアカウントに送信される可能性があることを理解したものとします。サービスに送信される情報は、本ポリシーの対象となります。

 f.当社が収集する個人情報により、当社はお客様のリクエストに対応し、当社の製品とサービスを改善し、お客様に表示される広告とコンテンツをカスタマイズし、新製品についてお客様に連絡することができます。

は、2011 年の設立以来 9,000 万人を超えるユーザーがおり、40 以上のカテゴリと 60 以上の言語にわたる数千の雑誌や新聞を擁する、世界最大かつ急速に成長しているセルフサービスのクロスプラットフォーム デジタル ニューススタンドです。ニューヨークに本社を置く Magzter は、アムステルダム、ロンドン、メキシコシティ、チェンナイ、ムンバイ、ニューデリー、バンガロール、シンガポールに現地拠点を置いており、間もなく他の国にも拡大する予定です。 2011 年 6 月に世界的起業家であるギリッシュ ラムダス氏とビジェイ ラダクリシュナン氏によって設立された Magzter は、世界中の雑誌や新聞の出版社が自社のタイトルのデジタル版を作成し、世界中の消費者に配信できるようにします。

 n.また、ユーザーが当社の利用規約を遵守していることを確認するために、使用状況情報も使用されます。たとえば、ユーザーの使用状況情報は、ユーザーが雑誌やその他のコンテンツを許可された回数、または許可された数のデバイスにのみダウンロードしていることを確認するのに役立ちます。

これにより、デジタル読者は月額購読料で 9,000 以上の雑誌や新聞に無制限にアクセスできるようになります。 Magzter はまた、アプリ向けの革新的な ezRead 2.0 機能により、世界最大の記事数を誇ります。これにより、スマートフォンや小さな画面のモバイル ユーザーは、本来の楽しみ方で雑誌コンテンツを楽しむことができます。読みやすく、素晴らしいビデオと高解像度の写真が付いています。

Bio Spectrum - September 2023

Bio Spectrum - September 2023

この問題で

Bio Spectrum Magazine Description: